Bahram Valamehr

2019

In 2019, Bahram Valamehr earned a total compensation of $2.8M as Chief Research and Development Officer at Fate Therapeutics, a 9% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$150,938
Option Awards$1,547,898
Salary$375,000
Stock Awards$744,750
Total$2,818,586

Valamehr received $1.5M in option awards, accounting for 55% of the total pay in 2019.

Valamehr also received $150.9K in non-equity incentive plan, $375K in salary and $744.8K in stock awards.

Rankings

In 2019, Bahram Valamehr's compensation ranked 4,340th out of 13,971 executives tracked by ExecPay. In other words, Valamehr earned more than 68.9% of executives.

ClassificationRankingPercentile
All
4,340
out of 13,971
69th
Division
Manufacturing
1,596
out of 5,701
72nd
Major group
Chemicals And Allied Products
558
out of 2,200
75th
Industry group
Drugs
470
out of 1,886
75th
Industry
Biological Products, Except Diagnostic Substances
101
out of 389
74th
Source: SEC filing on April 21, 2021.

Valamehr's colleagues

We found three more compensation records of executives who worked with Bahram Valamehr at Fate Therapeutics in 2019.

2019

J Wolchko

Fate Therapeutics

Chief Executive Officer

2019

Cindy Tahl

Fate Therapeutics

General Counsel

2019

Daniel Shoemaker

Fate Therapeutics

Chief Scientific Officer

News

In-depth

You may also like